Fang Zheng

Fang Zheng

Auto-generated profile, based on publicly available information

Fang Zheng

Section of Immunology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P.R. China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
QZQunfang Zhang
Qunfang Zhang
FZFang Zheng
Fang Zheng
YCYuchao Chen
Yuchao Chen
CLChun-Ling Liang
Chun-Ling Liang
HLHuazhen Liu
Huazhen Liu
ZDZhenhua Dai
Zhenhua Dai
Chimeric antigen receptor (CAR) T cells are emerging as an effective antitumoral therapy. However, their therapeutic effects on solid tumors are limited because of their short survival time and the immunosuppressive tumor microenvironment. Memory T cells respond more vigorously and persist longer than their naïve/effector counterparts. Therefore, promoting CAR T-cell development into memory T cells could further enhance their antitumoral effects. HI-TOPK-032 is a T-LAK cell–originated protein kinase (TOPK)-specific inhibitor that moderately represses some types of tumors. However, it is unknown whether HI-TOPK-032 works on hepatocellular carcinoma (HCC) and whether it impacts antitumoral immunity. Using both subcutaneous and orthotopic xenograft tumor models of two human HCC cell lines, Huh-7 and HepG2, we found that HI-TOPK-032 significantly improved proliferation/persistence of CD8+ CAR T cells, as evidenced by an increase in CAR T-cell counts or frequency of Ki-67+CD8+ cells and a decrease in PD-1+LAG-3+TIM-3+CD8+ CAR T cells in vivo. Although HI-TOPK-032 did not significantly suppress HCC growth, it enhanced the capacity of CAR T cells to inhibit tumor growth. Moreover, HI-TOPK-032 augmented central memory CD8+ T cell (TCM) frequency while increasing eomesodermin expression in CD8+ CAR T cells in tumor-bearing mice. Moreover, it augmented CD8+ CAR TCM cells in vitro and reduced their expression of immune checkpoint molecules. Finally, HI-TOPK-032 inhibited mTOR activation in CAR T cells in vitro and in tumors, whereas overactivation of mTOR reversed the effects of HI-TOPK-032 on CD8+ TCM cells and tumor growth. Thus, our studies have revealed mechanisms underlying the antitumoral effects of HI-TOPK-032 while advancing CAR T-cell immunotherapy.

17 June 2026
Verified
Other
Open access
QZQunfang Zhang
Qunfang Zhang
FZFang Zheng
Fang Zheng
YCYuchao Chen
Yuchao Chen
CLChun-Ling Liang
Chun-Ling Liang
HLHuazhen Liu
Huazhen Liu
ZDZhenhua Dai
Zhenhua Dai
Chimeric antigen receptor (CAR) T cells are emerging as an effective antitumoral therapy. However, their therapeutic effects on solid tumors are limited because of their short survival time and the immunosuppressive tumor microenvironment. Memory T cells respond more vigorously and persist longer than their naïve/effector counterparts. Therefore, promoting CAR T-cell development into memory T cells could further enhance their antitumoral effects. HI-TOPK-032 is a T-LAK cell–originated protein kinase (TOPK)-specific inhibitor that moderately represses some types of tumors. However, it is unknown whether HI-TOPK-032 works on hepatocellular carcinoma (HCC) and whether it impacts antitumoral immunity. Using both subcutaneous and orthotopic xenograft tumor models of two human HCC cell lines, Huh-7 and HepG2, we found that HI-TOPK-032 significantly improved proliferation/persistence of CD8+ CAR T cells, as evidenced by an increase in CAR T-cell counts or frequency of Ki-67+CD8+ cells and a decrease in PD-1+LAG-3+TIM-3+CD8+ CAR T cells in vivo. Although HI-TOPK-032 did not significantly suppress HCC growth, it enhanced the capacity of CAR T cells to inhibit tumor growth. Moreover, HI-TOPK-032 augmented central memory CD8+ T cell (TCM) frequency while increasing eomesodermin expression in CD8+ CAR T cells in tumor-bearing mice. Moreover, it augmented CD8+ CAR TCM cells in vitro and reduced their expression of immune checkpoint molecules. Finally, HI-TOPK-032 inhibited mTOR activation in CAR T cells in vitro and in tumors, whereas overactivation of mTOR reversed the effects of HI-TOPK-032 on CD8+ TCM cells and tumor growth. Thus, our studies have revealed mechanisms underlying the antitumoral effects of HI-TOPK-032 while advancing CAR T-cell immunotherapy.

2 May 2024
Verified
Other
Open access
QZQunfang Zhang
Qunfang Zhang
FZFang Zheng
Fang Zheng
YCYuchao Chen
Yuchao Chen
CLChun-Ling Liang
Chun-Ling Liang
HLHuazhen Liu
Huazhen Liu
ZDZhenhua Dai
Zhenhua Dai
Activation of mTOR diminishes the effects of HI-TOPK-032 on GPC3-CAR-T therapy and reduces CD8+ TCM frequency in tumor-bearing mice.

2 May 2024
Verified
Other
Open access
QZQunfang Zhang
Qunfang Zhang
FZFang Zheng
Fang Zheng
YCYuchao Chen
Yuchao Chen
CLChun-Ling Liang
Chun-Ling Liang
HLHuazhen Liu
Huazhen Liu
ZDZhenhua Dai
Zhenhua Dai
The gene or protein expression of GPC3-CAR.

17 June 2026
Verified
Other
Open access
QZQunfang Zhang
Qunfang Zhang
FZFang Zheng
Fang Zheng
YCYuchao Chen
Yuchao Chen
CLChun-Ling Liang
Chun-Ling Liang
HLHuazhen Liu
Huazhen Liu
ZDZhenhua Dai
Zhenhua Dai
The gene or protein expression of GPC3-CAR.

17 June 2026
Verified
Other
Open access
QZQunfang Zhang
Qunfang Zhang
FZFang Zheng
Fang Zheng
YCYuchao Chen
Yuchao Chen
CLChun-Ling Liang
Chun-Ling Liang
HLHuazhen Liu
Huazhen Liu
ZDZhenhua Dai
Zhenhua Dai
HI-TOPK-032 enhances the specific effector responses of CAR-T cells to GPC3.